Publications
DSUVIA®
1. Primary Manuscript for SAP301
2. Primary Manuscript for SAP302 (open-label study)
3. Primary Manuscript for SAP303 (open-label study)
4. DSUVIA PK Manuscript
5. Miner Safety Review Manuscript
6. DSUVIA: A Pooled Dosing and Efficacy Analysis Across Demographic Subgroups
7. DSUVIA Real-World Study: Ambulatory Surgery Setting
8. DSUVIA Real-World Study: Perioperative Pain Management
9. DSUVIA: A Pooled Demographic Analysis of Satisfaction and Safety
10. DSUVIA Real-World Study: Total Hip and Total Knee Arthroplasties
11. DSUVIA Use in the Military
12. DSUVIA Editorial
13. DSUVIA Real-World Study: Awake Plastic Surgery Procedures
14. DSUVIA Use in Interventional Pain Procedures
15. DSUVIA Real-World Study: Radiofrequency Microneedling Procedures
ZALVISO®
ZALVISO is an investigational drug. It is not approved by the FDA. AcelRx makes no claims regarding the safety or effectiveness of ZALVISO.
1. ZALVISO PK Manuscript
2. Primary Manuscript for Phase 3 ZALVISO study IAP309
3. Primary Manuscript for Phase 3 ZALVISO study IAP310
4. Primary Manuscript for Phase 3 ZALVISO study IAP311
Health Economics and Outcomes Research Articles
1. HEOR Study – Cost of IV Analgesia in the Emergency Department
2. HEOR Study – Cost of IV Morphine in the EU
3. HEOR Study – Cost of IV PCA
4. HEOR Study – A Commentary on Opioid Stewardship: Fentanyl, Sufentanil, and Perioperative Pain
This information is NOT presented to make safety or efficacy claims about our products. The intent of providing this information is to disseminate scientific literature currently available about our products. Please read each study to understand the strengths and limitations of the data.